Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-05-02
2008-05-06
Hayes, Robert C. (Department: 1649)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S014800, C514S016700, C514S015800, C514S013800
Reexamination Certificate
active
07368429
ABSTRACT:
Human myelin basic protein (h-MBP) has a molecular weight of 18.5 KD and contains 170 amino acid residues. Synthetic peptides ranging in length from about 8 to 25 residues and covering the entire length of the protein have been produced. Antibodies to h-MBP (anti-MBP) were found to be neutralized by the synthetic peptides, in vitro, which span the h-MBP from about amino acid residue 61 to about amino acid residue 106. The peptides, which cover both the amino (about residues 1 to 63) and carboxy (about residues 117 to 162) terminals of h-MBP did not neutralize purified anti-MBP. Intrathecal administratin of peptide MBP(75-95), MBP(86-95), or MBP(82-98) produced complete binding-neutralization of free (F) anti-MBP with no change in bound (B) levels. A control peptide MBP35-58 had no effect on F or B anti-MBP levels. Intravenous administration of MBP(75-95), MBP(86-95), or MBP(82-98) resulted in significant decline of F and B CSF anti-MBP levels. Administration of MBP synthetic peptides to MS patients either intrathecally or intravenously did not have any adverse neurological effects and systemic complications did not occur. The MBP epitope for MS anti-MBP has been localized to an area between amino acid 86 and amino acid 95.
REFERENCES:
patent: 3864481 (1975-02-01), Hashim
patent: 4113858 (1978-09-01), Hashim
patent: 4230696 (1980-10-01), Hashim
patent: 5571499 (1996-11-01), Hafler et al.
patent: 5571500 (1996-11-01), Hafler et al.
patent: 5641474 (1997-06-01), Hafler et al.
patent: 5645820 (1997-07-01), Hafler et al.
patent: 5817629 (1998-10-01), Warren et al.
patent: 5858364 (1999-01-01), Weiner et al.
patent: 5858980 (1999-01-01), Weiner et al.
patent: 5869054 (1999-02-01), Weiner et al.
patent: 5935577 (1999-08-01), Weiner et al.
patent: 5948764 (1999-09-01), Gaur et al.
patent: 6036957 (2000-03-01), Weiner et al.
patent: 6039947 (2000-03-01), Weiner et al.
patent: 6252040 (2001-06-01), Warren et al.
patent: 7090982 (2006-08-01), Warren et al.
patent: 0304279 (1989-02-01), None
patent: 0340109 (1989-11-01), None
patent: 0383620 (1990-08-01), None
patent: 80/02501 (1980-11-01), None
patent: WO 80/02501 (1980-11-01), None
patent: 88/00057 (1988-01-01), None
patent: WO 88/00057 (1988-01-01), None
patent: 88/10120 (1988-12-01), None
patent: 91/15225 (1991-10-01), None
patent: 93/08212 (1993-04-01), None
patent: 93/21222 (1993-10-01), None
patent: 95/31990 (1995-11-01), None
patent: WO 95/31990 (1995-11-01), None
patent: 96/12731 (1996-05-01), None
patent: 96/12737 (1996-05-01), None
patent: 96/16085 (1996-05-01), None
patent: 96/16086 (1996-05-01), None
patent: 96/28470 (1996-09-01), None
Alberts 1994. Molecular Biology of the Cell, pp. 1206-1220.
Kamholz et al. 1986. Proc Natl Acad Sci USA 83:4962-4966.
Groome, N., et al., “Preparation and Properties of Monoclonal Antibodies to Myelin Basic Protein and Its Peptides,” Neurochem. Int., 7:309-317 (1985).
Heuby, S., et al., “Monoclonal Antibodies Reactive with Myelin Basic Protein”, Molecular Immunology, 24:1359-1364 (1987).
Barry, R., et al., “Characterization of Myelin Basic Protein Catabolism Products in the Cerebrospinal Fluid from Multiple Sclerosis Stroke and Head Injury Patients,” Neurochem. Int., 18:291-300 (1991).
Ota, K., et al., “T-Cell Recognition of an Immunodominant Myelin Basic Protein Epitope in Multiple Sclerosis,” Nature 346:183-187 (1990).
Baxevanis, C.N., et al., “Peptides of Myelin Basic Portein Stimulate T Lymphocytes from Patients with Multiple Sclerosis”, J. of Neuroimmunology, 22:23-30 (1989).
Martin, R., et al., “A Myelin Basic Protein Peptide is Recognized by Cytotoxic T. Cells in the Context of Four HLA-DR Types Associated with Multiple Sclerosis,” The Journal of Experimental Medicine, 173:19-24 (1991).
Eylar, E.H., et al., “Suppression and Reversal of Allergic Encephalomyelitis in Rhesus Monkeys with Basic Protein and Peptides,” Neurochemical Research, 4:249-258 (1979).
Martin, R., et al., “Fine Specificity and HLA Restriction of Myelin Basic Protein Specific Cytotoxic T Cell Lines from Multiple Sclerosis Patients and Healthy Individuals,” The Journal of Immunology, 145:540-548 (1990).
Chou, Y.K., et al., Response of Human T Lymphocyte Lines to Myelin Basic Protein: Association of Dominant Epitopes with HLA Class II Restriction Molecules, Journal of Neuroscience Research, 23:207-216 (1989).
Sakai, K., et al., “Prevention of Experimental Encephalomyelitis with Peptides that Block Interaction of T Cells with Major Histocompatibility Complex Proteins,” Proc. Natl. Acad. Sci, USA, 86:9470-9474 (1989).
Higgins, et al., “Suppression of Experimental Autoimmune Encephalomyelitis by Oral Administratio of Myelin Basic Protein and Its Fragments,” Chemical Abstracts 108(19): 514 Abstract #165933t (1988).
Warren, et al., “Neutralization of Anti-Myelin Basic Protein by Cerebrospinal Fluid of Multiple Sclerosis Patients in Clinical Remission,” J. Neurol. Sci., 88:185-194 (1988).
Warren, et al., “A Correlation Between Cerebrospinal Fluid Myelin Basic Protein and anti-Myelin Basic Protein in Multiple Sclerosis Patients,” Ann. Neurol., 21:183-189 (1987).
Catz, et al., Detection of Anti-Myelin Basic Protein Neutralizing Factor in the CSF of MS Patients in Remission, Recent Advances in Multiple Sclerosis Therapy, 87-90 (1989).
Tourteltette, et al., “Multiple Sclerosis: The Blood-Brain Barrier and the Measurement of de novo central nervous system IgG synthesis”, Neurology 28(2):76-83 (1978).
Link, et al., Principles of Albumin and IigG Analyses in Neurological Disorders. III. Evaluation of IgG Synbthesis Withing the Central Nervous System in Multiple Sclerosis, Scand. J. Clin. Lab. Invest. 37:397-401 (1977).
Daibler, et al., “Large Scale Preparation of Myelin Basic Protein From Central Nervous Tissue of Several Mammalian Species,” Preparative Biochemistry, 2(2):139-165 (1972).
Tourtellette, “On Cerebrospinal Fluid Immunoglobulin-G (IgG) Quotients in multiple Sclerosis and Other Diseases”, Journal of Neurological Sciences, 10:279-304 (1970).
Warren, et al., “Cerebrospinal Fluid Antibodies to Myelin Basis Protein in Acute Idiopathic Optic Neuritis”, Ann. Neurol. 23:297-299 (1988).
Vandenbark, et al., Determinnants of Human Myelin Basic Protein That Induce Encephalitogenic T Cells in Lewis Rats, The Journal of Immunology, 143(11):3512-3516 (1989).
Groome, et al., “New Monoclonal Antibodies Reactive with Defined Sequential Epitopes in Human Myelin Basic Protein,” Chemical Abstracts 110(1):558 Abstract #5882p (1989).
Katz, et al., “Antigenic and Structural Characterization of Multiple Subpopulations of H3N2 Influenza Virus from an Individual,” Chemical Abstracts 109(19):548 Abstract #168486f (1988).
Gilliom, et al., “Separation of Myelin Basic Protein Peptide 43-88 and its Fragments by Analytic and Preparative High-Performance Liquid Chromatography,” Chemical Abstracts 98(13): 304 Abstract #103708q (1983).
Warren, et al., “Cerebrospinal Fluid Autoantibodies to Myelin Basic Protein in Multiple Sclerosis Patients,” J. Neurol. Sci., 91:143-151 (1989).
Warren, et al., “A Myelin Basis Protein Antibody Cascade in Purified IgG from Cerebrospinal Fluid of Multiple Sclerosis,” J. Neurol. Sci., 96:1927 (1990).
Warren, et al., “Diagnostic Value of Cerebrospinal Fluid Anti-Myelin Basic Protein in Patients with Multiple Sclerosis,” Ann. Neurol., 209:20-25 (1986).
Campbell, et al, “Myelin Basic Protein Administration in Multiple Scelrosis,” Arch. Neurol., 29:10-15 (1973).
Gonsette, et al., “Failure of Basic Protein Therapy for Multiple Sclerosis,” J. Neurol., 216:27-31 (1977).
Romine, et al., “A Study of Myelin Basic Protein as a Therapeutic Probe in Patients with Multiple Sclerosis,”In Multiple Sclerosis, Hallpike et al., eds., Williams and Wilkins, Baltimore, pp. 621-630 (1982).
Pantich, et al.,
Catz Ingrid
Warren Kenneth G.
Hayes Robert C.
Kolker Daniel E
Pillsbury Winthrop Shaw Pitman LLP
The Governors of the University of Alberta
LandOfFree
Peptide specificity of anti-myelin basic protein and the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptide specificity of anti-myelin basic protein and the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptide specificity of anti-myelin basic protein and the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3981926